摘要
目的:评价得舒特对肠易激综合征(IBS)的疗效。方法:56例根据罗马标准诊断为IBS的患者进入本研究。所有患者在服用得舒特治疗前一周服用安慰剂6天。安慰剂治疗无效的47例患者随后进入得舒特治疗,50mg,每日3次口服,疗程4周。结果:得舒特对肠易激综合征患者腹痛、腹泻和便秘单项症状的有效率分别为85.1%(40/47)、89.2%(33/37)和93.3%(14/15),对肠易激综合征的总有效率为85.1%(40/47)。治疗期间除2例诉头晕外,无其他不良反应。结论:得舒特治疗1BS疗效确切、副反应率低,临床上可作为治疗IBS的首选药物之一。
Background/Aims: To investigate the effectiveness of Dicetel, a calcium-channel blocker, in the treatment of the irritable bowel syndrome (IBS). Methods: Fifty six patients with IBS, diagnosed according to the Criteria of Roma, entered the study. All patients took placebo for six days in first week, only placebo-unresponder then received oral treatment of Dicetel 50mg tid for four weeks. Results: Total efficacy ra,tes for single symptom of IBS were as follows: abdominal pain 85.1% (40/47), diarrhea 89.2% (33/37) and constipation 93.3% (14/15). The global efficacy rate for IBS was 85.1% (40/47). During treatment, two patients complained of dizziness, and one of them was withdraw. Conclusions: Dicetel is highly effective and safe, and can be used as first-line drug for treatment of IBS.
出处
《胃肠病学》
1998年第2期110-111,共2页
Chinese Journal of Gastroenterology